Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
BörsenkürzelCODX
Name des UnternehmensCo-Diagnostics Inc
IPO-datumJul 12, 2017
CEOMr. Dwight H. Egan
Anzahl der mitarbeiter132
WertpapierartOrdinary Share
GeschäftsjahresendeJul 12
Addresse2401 S. Foothill Dr. Suite D
StadtSALT LAKE CITY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl84109
Telefon18014381036
Websitehttp://codiagnostics.com/
BörsenkürzelCODX
IPO-datumJul 12, 2017
CEOMr. Dwight H. Egan
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten